90767-09-2

Basic information

• Product Name: 2-(BROMOMETHYL)-6-NITROQUINOLINE
• Synonyms: 2-(BROMOMETHYL)-6-NITROQUINOLINE
• CAS NO: 90767-09-2
• Molecular Formula: C₁₀H₇BrN₂O₂
• Molecular Weight: 267.08
• Mol File: 90767-09-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(BROMOMETHYL)-6-NITROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(BROMOMETHYL)-6-NITROQUINOLINE(90767-09-2)
• EPA Substance Registry System: 2-(BROMOMETHYL)-6-NITROQUINOLINE(90767-09-2)

Safety Data

• Hazardous Substances Data: 90767-09-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-(Bromomethyl)-6-nitroquinoline is used as a building block in the preparation of various biologically active compounds, providing a foundation for the creation of new molecules with potential applications in medicine and agriculture.
Used in Pharmaceutical Production:
As an intermediate in the production of pharmaceuticals, 2-(Bromomethyl)-6-nitroquinoline plays a crucial role in the synthesis of drugs, contributing to the development of new treatments and therapies.
Used in Agrochemical Production:
2-(Bromomethyl)-6-nitroquinoline is also utilized as an intermediate in the production of agrochemicals, helping to develop new compounds for use in agriculture, such as pesticides and herbicides.
Used in Chemical Reactions and Transformations:
Due to its halogenated nature, 2-(Bromomethyl)-6-nitroquinoline is useful in certain types of chemical reactions and transformations, allowing for the modification and synthesis of new compounds with specific properties and applications.

Upstream product

• 613-30-9 2-methyl-6-nitroquinoline 

Relevant articles and documents

Copper(II) catalyzed heterobenzylic C(sp3)-H activation: Two efficient halogenation methodologies towards heterobenzyl halides

Two practical and simple synthetic methodologies towards various heterobenzyl halides were developed. A series of 2-halomethylquinolines were readily prepared by the one-pot reaction of 2-methylquinolines with CuX (X = I, Br, Cl) and TBHP in CH3CN. A large variety of heterobenzyl iodides, including 2-iodomethylquinolines, 2-iodomethylquinoxalines, 2-iodiomethylbenzooxazole, and 2-iodiomethylbenzothiazole, were efficiently synthesized by one-pot reaction of 2-methylheterocycles with iodine in the presence of CuSO4·5H2O in CH3CN.

Microwave-assisted α-halogenation of 2-methylquinolines with tetrabutylammonium iodide and 1,2-dichloroethane (1,2-dibromoethane)

A simple and efficient methodology permitting the halogenation of 2-methylquinolines into 2-(chloromethyl)quinolines or 2-(bromomethyl)quinolines in the tetrabutylammonium iodide and 1,2-dichloroethane (1,2-dibromoethane) system has been developed for the first time. The halogenation can be rapidly completed with good to excellent yields and high selectivity under microwave irradiation.

Heterocyclic mchr1 antagoists

This invention relates to novel heterocycles which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), also referred to as 11 CBy, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in

Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1

The high expression of MCH in the hypothalamus with the lean hypophagic phenotype coupled with increased resting metabolic rate and resistance to high fat diet-induced obesity of MCH KO mice has spurred considerable efforts to develop small molecule MCHR1 antagonists. Starting from a lead thienopyrimidinone series, structure-activity studies at the 3- and 6-positions of the thienopyrimidinone core afforded potent and selective MCHR1 antagonists with representative examples having suitable pharmacokinetic properties. Based on structure-activity relationships, a structural model for MCHR1 was constructed to explain the binding mode of these antagonists. In general, a good correlation was observed between pKas and activity in the right-hand side of the template, with Asp123 playing an important role in the enhancement of binding affinity. A representative example when evaluated chronically in diet-induced obese mice resulted in good weight loss effects. These antagonists provide a viable lead series in the discovery of new therapies for the treatment of obesity.